TP53 and obesity due to melanocortin 4 receptor deficiency: ,5 How p53 activates lipid metabolism in response to HFD treatment is not fully understood and it will be imperative to dissect the tissue- and cell-specific actions of p53 and its downstream signaling pathways in order to unravel a new paradigm of therapy for the chronic inflammatory state in obesity.